

Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM

Alan S. L. Wong^{a,b,1,2}, Gigi C. G. Choi^{a,b,1}, Cheryl H. Cui^{a,c,1}, Gabriela Pregonig^d, Pamela Milani^d, Miriam Adam^d, Samuel D. Perli^{a,e}, Samuel W. Kazer^{f,g,h}, Aleth Gaillard^{f,g,h}, Mario Hermann^{a,b}, Alex K. Shalek^{f,g,h}, Ernest Fraenkel^d, and Timothy K. Lu^{a,b,d,e,3}

^aSynthetic Biology Group, Massachusetts Institute of Technology (MIT) Synthetic Biology Center, MIT, Cambridge, MA 02139; ^bResearch Laboratory of Electronics, MIT, Cambridge, MA 02139; ^cHarvard University–MIT Division of Health Sciences and Technology, Cambridge, MA 02139; ^dDepartment of Biological Engineering, MIT, Cambridge, MA 02139; ^eDepartment of Electrical Engineering and Computer Science, MIT, Cambridge, MA 02139; ^fInstitute for Medical Engineering and Science and Department of Chemistry, MIT, Cambridge, MA 02139; ^gRagon Institute of Massachusetts General Hospital, MIT, and Harvard University, Cambridge, MA 02139; and ^hBroad Institute of MIT and Harvard University, Cambridge, MA 02142

Edited by Jennifer A. Doudna, University of California, Berkeley, CA, and approved December 31, 2015 (received for review September 15, 2015)

synbio
oxford



Max Jamilly | max.jamilly.com

Drug discovery is difficult

decline in oncology R&D


strong potential of epigenetic drugs





genomic screen for combination therapies

CRISPR

(hooray)

Combinatorial CRISPR-Cas9 in cancer cells





An innovative screening technique?

- false negatives
- dubious mathematical model
- need better CRISPR for frameshifts
- the future: functional combinatorial studies?